Business
Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy
Expedited Enrollment Surpassing 630 Targeted Participants Underscores the Strong Demand for a Therapy Focused on Vision Preservation Phase 3 ARCHER II Trial Design and Rationale to Be Presented at ASRS, a Leading Meeting for Retina Science and Innovation Topline Pivotal Phase 3 Data Expected in the Second Half of 2026 Potential for Vonaprument to Be the First Treatment Approved in Europe and the U.S. for Dry AMD with Geographic Atrophy Based on Protection of Visual Acuity and Structural Measures
About this update from Annexon, Inc.
[{"type":"image","alt":"Annexon Biosciences","displaySize":"","headline":null,"caption":"Annexon Biosciences","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":99,"url":"https://media.zenfs.com/en/globenewswire.com/578fc108e7e0712a28769323578aa13e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/5J35LGkHzjL3FW6lOBPAtA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/578fc108e7e0712a28769323578aa13e","width":300,"height":99}},"lazy":false},{"type":"text","content":"Expedited Enrollment Surpassing 630 Targeted Participants Underscores the Strong Demand for a Therapy Focused on Vision Preservation","length":132,"tagName":"p"},{"type":"text","content":"Phase 3 ARCHER II Trial Design and Rationale to Be Presented at ASRS, a Leading Meeting for Retina Science and Innovation","length":121,"tagName":"p"},{"type":"text","content":"Topline Pivotal Phase 3 Data Expected in the Second Half of 2026","length":64,"tagName":"p"},{"type":"text","content":"Potential for Vonaprument to Be the First Treatment Approved in Europe and the U.S. for Dry AMD with Geographic Atrophy Based on Protection of Visual Acuity and Structural Measures","length":180,"tagName":"p"},{"type":"text","content":"BRISBANE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced complete enrollment of the Phase 3 ARCHER II trial of vonaprument (formerly ANX007) for dry age-related macular degeneration (AMD) with geographic atrophy (GA), and the company remains on track to report topline data in the second half of 2026.","length":551,"tagName":"p"},{"type":"text","content":"Vonaprument is a first-in-kind, non-pegylated antigen-binding fragment (Fab) designed to block C1q locally in the eye with an intravitreal formulation. The neuroprotective effect and consistent benefits of C1q inhibition were previously demonstrated by vonaprument in a Phase 2 trial. Vonaprument is the only investigational therapy for dry AMD with GA to show significant vision preservation based upon best corrected visual acuity (BCVA) and low luminance visual acuity (LLVA).","length":479,"tagName":"p"},{"type...